Core Insights - ArriVent BioPharma, Inc. is presenting two significant poster presentations at the 2026 AACR Annual Meeting, focusing on innovative biopharmaceutical therapeutics for cancer treatment [1] Group 1: Firmonertinib - Firmonertinib is a novel EGFR inhibitor with high-resolution crystal structure data supporting its pivotal Phase 3 study in frontline EGFR exon 20 insertion mutant non-small cell lung cancer (NSCLC) [2] - The drug has shown early clinical evidence of activity against uncommon mutations, including exon 20 insertions and PACC variants, and is already approved in China for specific NSCLC cases [3][10] - Preclinical studies indicate firmonertinib's unique structural features enhance binding and activity against EGFR mutant proteins, demonstrating strong anti-tumor activity in various models [5][6] Group 2: ARR-002 - ARR-002, also known as AV-P138-ADC, is a dual-target tetravalent antibody drug conjugate (ADC) aimed at treating ovarian and endometrial cancers, characterized by its superior ADC potential [2][4] - The dual-target approach of ARR-002 is designed to overcome challenges faced by single-target ADCs, showing effective binding and enhanced internalization compared to single-target controls [7] - Initial preclinical data suggest ARR-002 has superior anti-tumor activity in ovarian cancer models, indicating its potential as a best-in-disease ADC [5][8] Group 3: Clinical Development - Firmonertinib is currently undergoing a global Phase 3 trial for first-line NSCLC patients with EGFR exon 20 insertion mutations and another for patients with EGFR PACC mutations [12] - ARR-002 is positioned for advancement towards clinical evaluation, with its development leveraging the unique characteristics of its dual-target mechanism [2][4] Group 4: Company Overview - ArriVent is dedicated to the identification, development, and commercialization of differentiated medicines to address unmet medical needs in cancer treatment [9] - The company aims to maximize the potential of its lead candidate, firmonertinib, while advancing a pipeline of novel therapeutics, including next-generation ADCs [9]

Forward-Looking Statements This presentation contains forward-looking statements regarding Kyntra Bio's strategy, future plans and prospects, including statements regarding its commercial products and clinical programs and those of its partners Fortis and UCSF. These forward-looking statements include, but are not limited to, statements regarding the efficacy, safety, and potential clinical or commercial success of Kyntra Bio products and product candidates, statements under the caption "Recent and Near-Ter ...

Core Insights - Day One Biopharmaceuticals (DAWN) has entered into a definitive agreement with Servier for the acquisition of all outstanding shares at $21.50 each, valuing the deal at approximately $2.5 billion [1][7] Group 1: Acquisition Details - The acquisition will enable Servier to add Ojemda, DAWN's first marketed drug, which received accelerated FDA approval in 2024 for treating relapsed or refractory pediatric low-grade glioma (pLGG) [2] - The deal is expected to close in the second quarter, with Servier planning to finance the transaction through existing cash and investments [3] Group 2: Financial Performance - Following the acquisition announcement, DAWN's stock price surged nearly 66%, and the stock has increased by 127% year-to-date compared to the industry's 4% growth [4] Group 3: Strategic Rationale - Servier's interest in DAWN aligns with its 2030 goal to develop innovative treatments across various therapeutic areas, including oncology [6] - Ojemda reported sales of $155.4 million for the full year 2025, reflecting a 172% year-over-year increase, with projected sales for 2026 estimated between $225 million and $250 million [6] Group 4: Portfolio Expansion - In addition to Ojemda, the acquisition will enhance Servier's oncology portfolio with two early-stage antibody drug conjugate (ADC) candidates, emiltatug ledadotin (emi-le) and DAY301, which are currently in separate early-stage studies [8] - This acquisition is part of Servier's broader strategy, which includes previous deals in the oncology space, such as licensing agreements with Black Diamond Therapeutics and Ideaya Biosciences [9]

Core Insights - Day One Biopharmaceuticals has successfully acquired Mersana Therapeutics, enhancing its pipeline with the clinical-stage antibody drug conjugate (ADC) emiltatug ledadotin (Emi-Le) targeting adenoid cystic carcinoma (ACC) [1][2][3] Acquisition Details - The acquisition involved purchasing all outstanding shares of Mersana at a price of $25 per share in cash, plus a non-tradable contingent value right (CVR) per share, potentially totaling up to $55.25 per share [3] - The tender offer for Mersana expired on January 5, 2026, with 3,029,135 shares validly tendered, representing 60.57% of Mersana's outstanding shares [4] Strategic Fit and Pipeline Expansion - The acquisition aligns with Day One's mission to expand into adult oncology while focusing on rare cancers, with Emi-Le showing promising early clinical data [2] - Emi-Le is directed against B7-H4, a target in certain cancers, including ACC, which has a significant unmet medical need [2][7] Company Background - Day One Biopharmaceuticals is dedicated to developing targeted therapies for life-threatening diseases, particularly in pediatric cancer, and aims to redefine cancer drug development [6][8]

The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this Application Proof, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this Application Proof. Application Proof of BioRay Biopharmaceutical Co., Ltd. 浙 江 博 銳 生 物 製 藥 股 份 有 限 公 司 (the "Company") (A joint stock company incorporated ...

Financial Highlights - FibroGen completed the sale of FibroGen China to AstraZeneca for approximately $220 million[3, 50] - The sale included an enterprise value of $85 million and approximately $135 million of FibroGen net cash held in China[50] - The company successfully repaid its term loan to Morgan Stanley Tactical Value[3, 50] - FibroGen extended its cash runway into 2028[3, 50] FG-3246 and FG-3180 Program (Prostate Cancer) - Phase 2 monotherapy trial of FG-3246 and FG-3180 in mCRPC (post-ARPI / pre-chemo setting) has been initiated, with interim results expected in 2H 2026[3, 17, 18] - In a Phase 1 monotherapy study, FG-3246 showed a median rPFS of 8.7 months and a PSA decline of >50% in approximately 36% of patients[15] - In a Phase 1b combination study with enzalutamide, FG-3246 showed a preliminary estimate of median rPFS of 10.2 months and PSA declines in 71% of evaluable patients[15] - Topline results from an investigator-sponsored trial (IST) of FG-3246 in combination with enzalutamide in mCRPC are expected in 1Q 2026[3, 15] Roxadustat (Anemia of LR-MDS) - Roxadustat is being developed as a late-stage development opportunity for anemia due to LR-MDS and high red blood cell transfusion burden[3, 36] - In a post-hoc analysis of the MATTERHORN Phase 3 trial, roxadustat showed promising transfusion independence (TI) benefits compared to placebo in patients with high transfusion burden, with 36% achieving 8-week RBC-TI within 28 weeks compared to 7% for placebo[37, 38] - Phase 3 protocol submission is anticipated in 4Q 2025 for roxadustat in anemia of LR-MDS, with potential Phase 3 initiation in 2026[3, 45]

Core Insights - Whitehawk Therapeutics reported a net loss of $17.7 million for Q3 2025, compared to a loss of $12.5 million in Q3 2024, indicating an increase in operational expenses [8][9] - The company is on track to file Investigational New Drug (IND) applications for its ADC candidates HWK-007 and HWK-016 by the end of 2025, with a third candidate, HWK-206, expected by mid-2026 [2][8] - Whitehawk's cash, cash equivalents, and short-term investments totaled $162.6 million as of September 30, 2025, a significant increase from $47.2 million at the end of 2024, providing a runway into 2028 for operations [8] Recent Operational Highlights - The company presented data at the AACR-NCI-EORTC conference, confirming PTK7 as a highly expressed tumor marker, which supports the potential of HWK-007 for treating approximately 750,000 patients in the US with PTK7-expressing cancers [2][10] - Whitehawk's ADC portfolio is designed to address limitations of first-generation therapies, with assets in-licensed from WuXi Biologics under an exclusive agreement [3][10] Financial Overview - Total current assets increased to $165.036 million as of September 30, 2025, from $61.287 million at the end of 2024, driven by higher cash and short-term investments [7][8] - Operating expenses for Q3 2025 were $19.546 million, slightly lower than $20.625 million in Q3 2024, with research and development expenses rising significantly to $14.345 million from $9.997 million year-over-year [9]

Core Insights - NextCure, Inc. is advancing its antibody-drug conjugate (ADC) programs, particularly SIM0505 and LNCB74, with significant progress in clinical trials and FDA approvals [2][3][4]. Business Highlights and Near-Term Milestones - The company has initiated U.S. enrollment in the Phase 1 trial for SIM0505, a CDH6-targeting ADC, at a mid-tier dose range where multiple clinical responses were previously observed in China [2][3]. - FDA clearance was received for a protocol amendment for LNCB74, allowing for higher dose escalation cohorts [2][4]. - Proof of concept data readouts for both SIM0505 and LNCB74 are expected in the first half of 2026 [2][4]. Financial Results for Quarter Ended September 30, 2025 - Cash, cash equivalents, and marketable securities decreased to $29.1 million from $68.6 million as of December 31, 2024, primarily due to operational funding and a $12.0 million upfront license fee to Simcere Zaiming [5][10]. - Research and development expenses were $6.1 million, down from $8.8 million in the same quarter of 2024, attributed to lower costs from deprioritized programs and reduced personnel-related costs [5][10]. - General and administrative expenses decreased to $2.8 million from $3.7 million year-over-year, mainly due to lower personnel costs [5][10]. - The net loss for the quarter was $8.6 million, an improvement from a net loss of $11.5 million in the same quarter of 2024 [5][10]. Selected Financial Information - Total assets as of September 30, 2025, were $39.6 million, down from $80.9 million as of December 31, 2024 [11]. - Total stockholders' equity decreased to $23.6 million from $65.5 million [11].

Core Insights - Pyxis Oncology is advancing its lead candidate, micvotabart pelidotin (MICVO), targeting recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) with preliminary data expected in Q4 2025 [1][5] Pipeline & Clinical Updates - Ongoing Phase 1 clinical studies of MICVO include monotherapy and combination approaches, with a focus on 2L/3L R/M HNSCC patients and a collaboration with Merck for combination therapy with KEYTRUDA® [4][5] - Preliminary data from the Phase 1 monotherapy dose expansion study and the Phase 1/2 combination dose escalation study will be presented, highlighting MICVO's unique mechanism of action and its potential to improve treatment outcomes [4][5] - Recent translational data presented at ESMO 2025 and AACR-NCI-EORTC provided insights into MICVO's pharmacodynamics and its effects on tumor microenvironment remodeling and immune activation [4][5] Financial Results - As of September 30, 2025, Pyxis Oncology reported cash and cash equivalents of $77.7 million, sufficient to fund operations into the second half of 2026 [11] - Research and development expenses for Q3 2025 were $17.8 million, slightly up from $17.7 million in Q3 2024, with a notable increase in MICVO program-specific costs [11] - The net loss for Q3 2025 was $22.0 million, consistent with the previous year, reflecting ongoing investment in clinical development [11][14]

Core Insights - Whitehawk Therapeutics presented data on Protein Tyrosine Kinase 7 (PTK7) as a promising target for antibody-drug conjugates (ADCs) at the 2025 AACR-NCI-EORTC International Conference, highlighting its expression in approximately 70% of solid tumors [1][6][3] Group 1: PTK7 Characteristics - PTK7 is the third most highly expressed tumor marker among ADC targets, following HER2 and HER3, with stable expression across various cancer types and stages [6][1] - The analysis involved over 157,000 tumor samples, confirming PTK7's broad expression in solid tumors, particularly in endometrial (7.4), ovarian (7.2), head and neck (7.1), non-small cell lung cancer (NSCLC) (6.9), and breast (6.7) tumors [6][3] Group 2: Development of HWK-007 - Whitehawk is advancing HWK-007, a PTK7-targeting ADC that utilizes a stable yet cleavable linker to deliver a Topoisomerase I (TOPO1) inhibitor payload, with plans to submit an Investigational New Drug application to the FDA by year-end [5][6] - The company aims to initiate clinical evaluations of HWK-007 in NSCLC, ovarian, and endometrial cancers, targeting nearly 750,000 patients in the US with PTK7-expressing cancers [7][5] Group 3: Collaboration and Future Outlook - The analysis was conducted in collaboration with Tempus AI, utilizing real-world data to characterize PTK7 expression for the first time [1][7] - The findings underscore the potential of PTK7 as a clinically meaningful target for ADCs, reinforcing Whitehawk's strategic focus on developing next-generation ADCs for a wide range of patients [5][6]